AbbVie says Phase 3 AFFIRM trial shows subcutaneous Skyrizi lifts endoscopic remission in Crohn’s disease patients
ABBV•AbbVie said Phase 3 AFFIRM results showed subcutaneous Skyrizi improved endoscopic remission in moderate-to-severe Crohn’s disease versus placebo. Safety through week 24 aligned with the established profile, with no new safety signals reported.
1. AFFIRM trial results
AbbVie released Phase 3 AFFIRM results for subcutaneous Skyrizi in moderate-to-severe Crohn’s disease, presented at ACG 2026. The results showed improved intestinal healing outcomes versus placebo and build on previously presented week 12 findings showing Skyrizi beat placebo on clinical remission and endoscopic response. AbbVie is seeking FDA approval for subcutaneous induction dosing in Crohn’s disease.
